Short-interfering RNA (siRNA)-induced RNAi responses have great potential to treat a wide
variety of human diseases from cancer to pandemic viral outbreaks to Parkinson's Disease …

Significant progress has been made in the advancement of RNAi therapeutics by combining
a synthetic triantennary N-acetylgalactosamine ligand targeting the asialoglycoprotein …

Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand
derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to …

The hepatocyte-specific asialoglycoprotein receptor (ASGPR) is an ideal candidate for
targeted drug delivery to the liver due to its high capacity for substrate clearance from …

Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-
acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is …

The potential therapeutic application of oligonucleotides (ONs) that selectively suppress
target genes through antisense and RNA interference mechanisms has attracted great …

Advancement of RNAi-based therapeutics depends on effective delivery to the site of protein
synthesis. Although intravenously administered, multi-component delivery vehicles have …

One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the
remarkable durability of silencing that can persist for months in preclinical species and …

Covalent attachment of a synthetic triantennary N-acetylagalactosamine (GalNAc) ligand to
chemically modified siRNA has enabled asialoglycoprotein (ASGPR)-mediated targeted …

A main challenge in realizing the full potential of nucleic acid therapeutics is efficient
delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well …